Altimmune, Inc.

Case Overview
40 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 10/06/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Altimmune, Inc. |
Court: | Court: District of Maryland |
Case Number: | Case Number: 8:25cv02581 |
Class Period: | Class Period: 08/10/2023 - 06/25/2025 |
Ticker: | Ticker: ALT |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Maryland on behalf of those who acquired Altimmune, Inc. (“ALT” or the “Company”) (NASDAQ: ALT) securities during the period of August 10, 2023 through June 25, 2024, inclusive (“the Class Period”). Investors have until October 6, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. Following this news, the price of Altimmune's common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune's stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day.